Assessment of the Lipid Lowering Effect of Rosuvastatin Compared to Atorvastatin in Subjects With Coronary Heart Disease
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00235950|
Recruitment Status : Completed
First Posted : October 12, 2005
Last Update Posted : November 19, 2010
|Condition or disease||Intervention/treatment||Phase|
|Coronary Heart Disease||Drug: Rosuvastatin or atorvastatin or simvastatin and clopidogrel||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||255 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||A Multicentre Study Comparing the Efficacy of Rosuvastatin With Atorvastatin When Given for a Period of 16 Wks to Subjects With Coronary Heart Disease & a Previously Performed Percutaneous Coronary Intervention|
|Study Start Date :||January 2004|
|Actual Primary Completion Date :||March 2006|
|Actual Study Completion Date :||March 2006|
- Drug: Rosuvastatin or atorvastatin or simvastatin and clopidogrel
Other Name: Crestor
- Compare the efficacy of once daily treatment with rosuvastatin with the efficacy of treatment with atorvastatin
- Compare the impact of treatment with rosuvastatin to that of atorvastatin and simvastatin on clopidogrel initiated inhibition of platelet aggregation in a subset of subjects recruited in the Stockholm region.
- Compare the impact of treatment with rosuvastatin to that of atorvastatin on clopidogrel initiated inhibition of platelet aggregation in all subjects, totally and on each dose of rosuvastatin and atorvastatin.
- Compare the efficacy of treatment with rosuvastatin with the efficacy of treatment with atorvastatin in reducing LDL-C levels
- Compare the efficacy of once daily treatment with rosuvastatin with that of atorvastatin in modifying levels of TC, HDL-C, TG, nonHDL-C (TC-HDL-C), LDL-C
- Compare the titration schedule of rosuvastatin with that of atorvastatin.
- Determine the safety by evaluating the incidence and severity of adverse events and abnormal laboratory values through 16 weeks of treatment
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00235950
|Study Director:||AstraZeneca Medical Science Director, MD||AstraZeneca|